FDA's Crackdown On Drug Ads Conflicts With Precedent

The article examines the FDA’s 2025–2026 enforcement activity related to direct-to-consumer (DTC) prescription drug advertising, including increased oversight by the Office of Prescription Drug Promotion (OPDP) and a rise in warning and untitled letters. It describes how recent FDA communications address truthful, nonmisleading statements about approved indications, as well as advertising elements such as imagery, tone, and comparative messaging. The analysis outlines potential legal and constitutional considerations, including the application of First Amendment principles to commercial speech. Readers gain insight into evolving FDA enforcement approaches and the implications for pharmaceutical marketing and compliance practices. The article also highlights considerations for companies, including review of DTC advertising, substantiation of claims, and evaluation of creative content.